Company: GNMSF
Filing Date: 2025-08-07
Form Type: 6-K
Source: 0001434265-25-000063
Chunk: 26

Company: GENMAB A/S
Filing Date: 2025-08-07
Form: 6-K
Chunk 26
---
 in 3L+ DLBCL and the expansion to address a second indication, 3L+ FL, which was approved in June 2024. Net product sales of EPKINLY in the U.S. and Japan by Genmab were $175 million in the first six months of 2025 compared to $109 million in the first six months of 2024. EPKINLY was approved in the U.S. in May 2023 and in Japan in September 2023.

| Genmab A/S            
 Carl Jacobsens Vej 30 
 2500 Valby, Denmark   |     | Tel: +45 7020 2728 
 www.genmab.com     |     | Company Announcement no. 40 
 Page 17/44                  
 CVR no. 2102 3884           |

#### Interim Report for the First Half of 2025
Net sales of TEPKINLY in territories where Genmab receives royalty revenue were $36 million in the first six months of 2025 compared to $12 million in the first six months of 2024.

Refer to Financial Statement Note 3 in this interim report for further details about revenue.

Key Developments to Revenue – Second Quarter of 2025

Genmab’s revenue was $925 million for the second quarter of 2025 compared to $779 million for the second quarter of 2024. The increase of $146 million, or 19%, was primarily driven by higher DARZALEX and Kesimpta royalties achieved under our collaborations with J&J and Novartis, respectively, and increased EPKINLY net product sales, partly offset by reduced reimbursement revenue associated with Genmab assuming full control of development, as well as future commercialization, of the acasunlimab program, effective in the second half of 2024.

#### Royalties
Royalty revenue on net sales of DARZALEX was $638 million in the second quarter of 2025 compared to $538 million in the second quarter of 2024, an increase of $100 million, or 19%. Royalty revenue on net sales of Kesimpta was $108 million in the second quarter of 2025 compared to $80 million in the second quarter of 2024, an increase of $28 million, or 35%.

#### Net Product Sales
Global net sales of EPKINLY/TEPKINLY were $121 million in the second quarter